Abstract
Multiple sclerosis (MS) clinical research has produced remarkable results over the past two decades leading to 9 marketed therapies that alter disease course. We have learned a great deal about the science of MS clinical trials, especially for treatments with anti-inflammatory agents. Moving forward, we would now like to apply what we have learned to the new challenges of treating the degenerative aspects of this illness. Doing so will have benefits not only for MS, but potentially for other neurodegenerative diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
